参考文献/References:
[1] Hansson GK, Hermansson A. The immune system in atherosclerosis[J]. Nat Immunol, 2011, 12(3): 204-212.
[2] Tsukano H, Gotoh T, Endo M, et al. The endoplasmic reticulum stress-C/EBP homologous protein pathway-mediated apoptosis in macrophages contributes to the instability of atherosclerotic plaques[J]. Arterioscler Thromb Vasc Biol, 2010, 30(10): 1925-1932.
[3] Tabas I. Macrophage apoptosis in atherosclerosis: consequences on plaque progression and the role of endoplasmic reticulum stress[J]. Antioxid Redox Signal,2009, 11(9): 2333-2339.
[4] Timmins JM, Ozcan L, Seimon TA, et al. Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways[J].J Clin Invest,2009, 119(10): 2925-2941.
[5] Guicciardi ME, Gores GJ. Life and death by death receptors[J]. FASEB J, 2009, 23(6): 1625-1637.
[6] Aflaki E, Radovic B, Chandak PG, et al. Triacylglycerol accumulation activates the mitochondrial apoptosis pathway in macrophages[J]. J Biol Chem, 2011, 286(9): 7418-7428.
[7] Tabas I. The role of endoplasmic reticulum stress in the progression of atherosclerosis[J]. Circ Res, 2010, 107(7): 839-850.
[8] Minamino T, Kitakaze M. ER stress in cardiovascular disease[J]. J Mol Cell Cardiol, 2010, 48(6): 1105-1110.
[9] Zechner R, Kienesberger PC, Haemmerle G, et al. Adipose triglyceride lipase and the lipolytic catabolism of cellular fat stores[J]. J Lipid Res, 2009, 50(1): 3-21.
[10] Saraswathi V, Hasty AH. Inhibition of long-chain acyl coenzyme A synthetases during fatty acid loading induces lipotoxicity in macrophages[J]. Arterioscler Thromb Vasc Biol, 2009, 29(11): 1937-1943.
[11] Aflaki E, Doddapattar P, Radovic B, et al. C16 ceramide is crucial for triacylglycerol-induced apoptosis in macrophages[J]. Cell Death Dis,2012, 3: e280.
[12] Yonetsu T, Kato K, Uemura S, et al. Features of coronary plaque in patients with metabolic syndrome and diabetes mellitus assessed by 3-vessel optical coherence tomography[J].Circ Cardiovasc Imaging,2013, 6(5): 665-673.
[13] Hartman ME, O'Connor JC, Godbout JP, et al. Insulin receptor substrate-2-dependent interleukin-4 signaling in macrophages is impaired in two models of type 2 diabetes mellitus[J]. J Biol Chem,2004, 279(27): 28045-28050.
[14] Tabas I, Tall A, Accili D. The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression[J]. Circ Res,2010, 106(1): 58-67.
[15] Han S, Liang CP, Devries-Seimon T, et al. Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions[J]. Cell Metab,2006, 3(4): 257-266.
[16] Rios FJ, Koga MM, Ferracini M, et al. Co-stimulation of PAFR and CD36 is required for oxLDL-induced human macrophages activation[J]. PLoS One,2012, 7(5): e36632.
[17] Senokuchi T, Liang CP, Seimon TA, et al. Forkhead transcription factors(FoxOs)promote apoptosis of insulin-resistant macrophages during cholesterol-induced endoplasmic reticulum stress[J]. Diabetes, 2008, 57(11): 2967-2976.
[18] Su D, Coudriet GM, Hyun KD, et al. FoxO1 links insulin resistance to proinflammatory cytokine IL-1beta production in macrophages[J]. Diabetes,2009, 58(11): 2624-2633.
[19] Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus[J]. J Clin Endocrinol Metab,2006, 91(1): 295-299.
[20] Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization[J]. Circulation,2007, 115(8): 972-980.
[21] 张高峰,许澎,乔祺. 内脂素对巨噬细胞凋亡的影响及其机制研究[J]. 中国临床医学,2011(05): 617-620.
[22] Lee S, Kwak HB. Role of adiponectin in metabolic and cardiovascular disease[J]. J Exerc Rehabil,2014, 10(2): 54-59.
[23] van Stijn CM, Kim J, Barish GD, et al. Adiponectin Expression Protects against Angiotensin II-Mediated Inflammation and Accelerated Atherosclerosis[J]. PLoS One,2014, 9(1): e86404.
[24] Mouquet F, Cuilleret F, Susen S, et al. Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1[J]. Eur Heart J,2009, 30(7): 840-849.
[25] Takeuchi S, Wada K, Uozumi Y, et al. Adiponectin receptor 1 expression is associated with carotid plaque stability[J]. Neurol India,2013, 61(3): 249-253.
[26] Yu S, Zhang Y, Li MZ, et al. Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients[J]. Chin Med J(Engl), 2012, 125(19): 3440-3444.
[27] Spiroglou SG, Kostopoulos CG, Varakis JN, et al. Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis[J]. J Atheroscler Thromb,2010, 17(2): 115-130.
[28] Goralski KB, Mccarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism[J]. J Biol Chem,2007, 282(38): 28175-28188.
[29] Dullaart RP, Vergeer M, de Vries R, et al. Type 2 diabetes mellitus interacts with obesity and common variations in PLTP to affect plasma phospholipid transfer protein activity[J]. J Intern Med,2012, 271(5): 490-498.
[30] Robins SJ, Lyass A, Brocia RW, et al. Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study[J].Atherosclerosis,2013, 228(1): 230-236.
[31] Samyn H, Moerland M, van Gent T, et al. Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice[J]. Atherosclerosis,2009, 204(2): 429-434.
[32] 张科. 磷脂转运蛋白对动脉粥样硬化斑块发展和稳定性作用的实验研究[D]. 山东大学,2012.
[33] Wehinger A, Tancevski I, Schgoer W, et al. Phospholipid transfer protein augments apoptosis in THP-1-derived macrophages induced by lipolyzed hypertriglyceridemic plasma[J].Arterioscler Thromb Vasc Biol,2007, 27(4): 908-915.
[34] Mahmoud F, Al-Ozairi E. Inflammatory cytokines and the risk of cardiovascular complications in type 2 diabetes[J].Dis Markers,2013, 35(4): 235-241.
[35] Butcher M, Galkina E. Current views on the functions of interleukin-17A-producing cells in atherosclerosis[J]. Thromb Haemost, 2011, 106(5): 787-795.
[36] Erbel C, Dengler TJ, Wangler S, et al. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability[J]. Basic Res Cardiol,2011, 106(1): 125-134.
[37] 高琦. Th17细胞及效应分子IL-17A在动脉粥样硬化发生过程中的作用及机制研究[D]. 山东大学,2012.
[38] Erbel C, Chen L, Bea F, et al. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice[J]. J Immunol,2009, 183(12): 8167-8175.
相似文献/References:
[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(05):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(05):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[4]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制
——2014年美国糖尿病协会“杰出科学成就奖”
演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[5]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[6]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[7]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[8]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[9]吕丹 李晓思 陈树春 王泽普.Betatrophin:糖尿病再生治疗的新希望[J].国际内分泌代谢杂志,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
Lyu Dan*,Li Xiaosi,Chen Shuchun,et al.Betatrophin:new hope for regeneration therapy of diabetes[J].International Journal of Endocrinology and Metabolism,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
[10]陈金安 柳岚 蒋克春 王爱萍.糖尿病足溃疡中趋化因子的作用及机制[J].国际内分泌代谢杂志,2015,(05):357.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.018]
Chen Jinan,Liu Lan,Jiang Kechun,et al.Roles of chemokines in diabetic foot ulcer and the mechanisms[J].International Journal of Endocrinology and Metabolism,2015,(05):357.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.018]